LABT — Lakewood-amedex Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Lakewood-amedex Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -8.28 | -4.86 | -3.85 |
| Depreciation | |||
| Non-Cash Items | 0.641 | 0.316 | 1.47 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.813 | -1.19 | 0.429 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -6.82 | -5.72 | -1.94 |
| Capital Expenditures | 0 | -0.002 | 0 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -3.78 | 3.93 | 0 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -3.78 | 3.92 | 0 |
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 0 | -0.05 | 1.5 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -10.6 | -1.85 | -0.445 |